• 7914 Citations
  • 39 h-Index
19952019

Research output per year

If you made any changes in Pure these will be visible here soon.

Research Output

Article

Ablation of a site of progression with stereotactic body radiation therapy extends sunitinib treatment from 14 to 22 months

Straka, C., Kim, D. W. N., Timmerman, R. D., Pedrosa, I., Jacobs, C. & Brugarolas, J., Aug 10 2013, In : Journal of Clinical Oncology. 31, 23, p. e401-e403

Research output: Contribution to journalArticle

21 Scopus citations

Addressing metabolic heterogeneity in clear cell renal cell carcinoma with quantitative Dixon MRI

Zhang, Y., Udayakumar, D., Cai, L., Hu, Z., Kapur, P., Kho, E. Y., Pavía-Jiménez, A., Fulkerson, M., de Leon, A. D., Yuan, Q., Dimitrov, I. E., Yokoo, T., Ye, J., Mitsche, M. A., Kim, H., McDonald, J. G., Xi, Y., Madhuranthakam, A. J., Dwivedi, D. K., Lenkinski, R. E. & 5 others, Cadeddu, J. A., Margulis, V., Brugarolas, J., DeBerardinis, R. J. & Pedrosa, I., Aug 3 2017, In : JCI insight. 2, 15

Research output: Contribution to journalArticle

Open Access
15 Scopus citations

An empirical approach leveraging tumorgrafts to dissect the tumor microenvironment in renal cell carcinoma identifies missing link to prognostic inflammatory factors

Wang, T., Lu, R., Kapur, P., Jaiswal, B. S., Hannan, R., Zhang, Z., Pedrosa, I., Luke, J. J., Zhang, H., Goldstein, L. D., Yousuf, Q., Gu, Y. F., McKenzie, T., Joyce, A., Kim, M. S., Wang, X., Luo, D., Onabolu, O., Stevens, C., Xie, Z. & 11 others, Chen, M., Filatenkov, A., Torrealba, J., Luo, X., Guo, W., He, J., Stawiski, E., Modrusan, Z., Durinck, S., Seshagiri, S. & Brugarolas, J., Sep 1 2018, In : Cancer Discovery. 8, 9, p. 1142-1155 14 p.

Research output: Contribution to journalArticle

14 Scopus citations

A novel germline mutation in BAP1 predisposes to familial clear-cell renal cell carcinoma

Farley, M. N., Schmidt, L. S., Mester, J. L., Peña-Llopis, S., Pavia-Jimenez, A., Christie, A., Vocke, C. D., Ricketts, C. J., Peterson, J., Middelton, L., Kinch, L., Grishin, N., Merino, M. J., Metwalli, A. R., Xing, C., Xie, X. J., Dahia, P. L. M., Eng, C., Linehan, W. M. & Brugarolas, J., Sep 1 2013, In : Molecular Cancer Research. 11, 9, p. 1061-1071 11 p.

Research output: Contribution to journalArticle

99 Scopus citations

A validated tumorgraft model reveals activity of dovitinib against renal cell carcinoma

Sivanand, S., Peña-Llopis, S., Zhao, H., Kucejova, B., Spence, P., Pavia-Jimenez, A., Yamasaki, T., McBride, D. J., Gillen, J., Wolff, N. C., Morlock, L., Lotan, Y., Raj, G., Sagalowsky, A. I., Margulis, V., Cadeddu, J. A., Ross, M. T., Bentley, D. R., Kabbani, W., Xie, X-J. & 3 others, Kapur, P., Williams, N. S. & Brugarolas, J. B., Jun 6 2012, In : Science Translational Medicine. 4, 137, 137ra75.

Research output: Contribution to journalArticle

113 Scopus citations

BAP1 and PBRM1 in metastatic clear cell renal cell carcinoma: tumor heterogeneity and concordance with paired primary tumor

Eckel-Passow, J. E., Serie, D. J., Cheville, J. C., Ho, T. H., Kapur, P., Brugarolas, J., Thompson, R. H., Leibovich, B. C., Kwon, E. D., Joseph, R. W. & Parker, A. S., Mar 21 2017, In : BMC Urology. 17, 1, p. 1-7 7 p.

Research output: Contribution to journalArticle

9 Scopus citations

BAP1 immunohistochemistry predicts outcomes in a multi-institutional cohort with clear cell renal cell carcinoma

Kapur, P., Christie, A., Raman, J. D., Then, M. T., Nuhn, P., Buchner, A., Bastian, P., Seitz, C., Shariat, S. F., Bensalah, K., Rioux-Leclercq, N., Xie, X-J., Lotan, Y., Margulis, V. & Brugarolas, J. B., Mar 1 2014, In : Journal of Urology. 191, 3, p. 603-610 8 p.

Research output: Contribution to journalArticle

46 Scopus citations

Bap1 is essential for kidney function and cooperates with Vhl in renal tumorigenesis

Wang, S. S., Gu, Y. F., Wolff, N., Stefanius, K., Christie, A., Dey, A., Hammer, R. E., Xie, X-J., Rakheja, D., Pedrosa, I., Carroll, T. J., McKay, R. M., Kapur, P. & Brugarolas, J. B., Nov 18 2014, In : Proceedings of the National Academy of Sciences of the United States of America. 111, 46, p. 16538-16543 6 p.

Research output: Contribution to journalArticle

69 Scopus citations

BAP1 loss defines a new class of renal cell carcinoma

Peña-Llopis, S., Vega-Rubín-De-Celis, S., Liao, A., Leng, N., Pavía-Jiménez, A., Wang, S., Yamasaki, T., Zhrebker, L., Sivanand, S., Spence, P., Kinch, L., Hambuch, T., Jain, S., Lotan, Y., Margulis, V., Sagalowsky, A. I., Summerour, P. B., Kabbani, W., Wong, S. W. W., Grishin, N. V. & 7 others, Laurent, M., Xie, X-J., Haudenschild, C. D., Ross, M. T., Bentley, D. R., Kapur, P. & Brugarolas, J. B., Jul 1 2012, In : Nature genetics. 44, 7, p. 751-759 9 p.

Research output: Contribution to journalArticle

475 Scopus citations

Cell-type-dependent regulation of mTORC1 by REDD1 and the tumor suppressors TSC1/TSC2 and LKB1 in response to hypoxia

Wolff, N. C., Vega-Rubin-de-Celis, S., Xie, X. J., Castrillon, D. H., Kabbani, W. & Brugarolas, J., May 2011, In : Molecular and cellular biology. 31, 9, p. 1870-1884 15 p.

Research output: Contribution to journalArticle

49 Scopus citations

Chemical inhibition of RNA viruses reveals REDD1 as a host defense factor

Mata, M. A., Satterly, N., Versteeg, G. A., Frantz, D., Wei, S., Williams, N., Schmolke, M., Peña-Llopis, S., Brugarolas, J., Forst, C. V., White, M. A., García-Sastre, A., Roth, M. G. & Fontoura, B. M. A., Oct 2011, In : Nature chemical biology. 7, 10, p. 712-719 8 p.

Research output: Contribution to journalArticle

50 Scopus citations

Clear Cell Renal Cell Carcinoma Subtypes Identified by BAP1 and PBRM1 Expression

Joseph, R. W., Kapur, P., Serie, D. J., Parasramka, M., Ho, T. H., Cheville, J. C., Frenkel, E., Parker, A. S. & Brugarolas, J., Jan 1 2016, In : Journal of Urology. 195, 1, p. 180-187 8 p.

Research output: Contribution to journalArticle

60 Scopus citations

DEFOR: Depth- and frequency-based somatic copy number alteration detector

Zhang, H., Zhan, X., Brugarolas, J. & Xie, Y., Oct 1 2019, In : Bioinformatics. 35, 19, p. 3824-3825 2 p.

Research output: Contribution to journalArticle

Open Access

Deletion of p21 cannot substitute for p53 loss in rescue of mdm2 null lethality

Montes de Oca Luna, R., Amelse, L. L., Chavez-Reyes, A., Evans, S. C., Brugarolas, J., Jacks, T. & Lozano, G., Aug 1 1997, In : Nature genetics. 16, 4, p. 336-337 2 p.

Research output: Contribution to journalArticle

16 Scopus citations
11 Scopus citations

Discontinuing VEGF-targeted Therapy for Progression Versus Toxicity Affects Outcomes of Second-line Therapies in Metastatic Renal Cell Carcinoma

De Velasco, G., Xie, W., Donskov, F., Albiges, L., Beuselinck, B., Srinivas, S., Agarwal, N., Lee, J. L., Brugarolas, J., Wood, L. A., Rha, S. Y., Kollmannsberger, C., North, S., Kanesvaran, R., Rini, B. I., Broom, R., Yamamoto, H., Kaymakcalan, M. D., Heng, D. Y. C. & Choueiri, T. K., Nov 7 2016, (Accepted/In press) In : Clinical Genitourinary Cancer.

Research output: Contribution to journalArticle

6 Scopus citations

Downregulation of human DAB2IP gene expression in renal cell carcinoma results in resistance to ionizing radiation

Yun, E. J., Lin, C. J., Dang, A., Hernandez, E., Guo, J., Chen, W. M., Allison, J., Kim, N., Kapur, P., Brugarolas, J. B., Wu, K., He, D., Lai, C. H., Lin, H., Saha, D., Baek, S. T., Chen, P. B. & Hsieh, J-T., Jan 1 2019, In : Clinical Cancer Research. 25, 14, p. 4542-4551 10 p.

Research output: Contribution to journalArticle

Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: A retrospective analysis with independent validation

Kapur, P., Peña-Llopis, S., Christie, A., Zhrebker, L., Pavía-Jiménez, A., Rathmell, W. K., Xie, X. J. & Brugarolas, J., Feb 1 2013, In : The Lancet Oncology. 14, 2, p. 159-167 9 p.

Research output: Contribution to journalArticle

240 Scopus citations

Establishing a human renal cell carcinoma tumorgraft platform for preclinical drug testing

Pavía-Jiménez, A., Tcheuyap, V. T. & Brugarolas, J., Aug 2014, In : Nature Protocols. 9, 8, p. 1848-1859 12 p.

Research output: Contribution to journalArticle

28 Scopus citations

Exploring a glycolytic inhibitor for the treatment of an FH-deficient type-2 papillary RCC

Yamasaki, T., Tran, T. A. T., Oz, O. K., Raj, G. V., Schwarz, R. E., DeBerardinis, R. J., Zhang, X. & Brugarolas, J., Apr 1 2011, In : Nature Reviews Urology. 8, 3, p. 165-171 7 p.

Research output: Contribution to journalArticle

28 Scopus citations

Fibroblast growth factor receptor-dependent and -independent paracrine signaling by sunitinib-resistant renal cell carcinoma

Tran, T. A., Leong, H. S., Pavia-Jimenez, A., Fedyshyn, S., Yang, J., Kucejova, B., Sivanand, S., Spence, P., Xie, X. J., Peña-Llopis, S., Power, N. & Brugarolas, J., 2016, In : Molecular and Cellular Biology. 36, 13, p. 1836-1855 20 p.

Research output: Contribution to journalArticle

16 Scopus citations

Hepatic mTORC1 Opposes Impaired Insulin Action to Control Mitochondrial Metabolism in Obesity

Kucejova, B., Duarte, J., Satapati, S., Fu, X., Ilkayeva, O., Newgard, C. B., Brugarolas, J. & Burgess, S. C., Jul 12 2016, In : Cell Reports. 16, 2, p. 508-519 12 p.

Research output: Contribution to journalArticle

13 Scopus citations

High-throughput simultaneous screen and counterscreen identifies homoharringtonine as synthetic lethal with von Hippel-Lindau loss in renal cell carcinoma

Wolff, N. C., Pavía-Jiménez, A., Tcheuyap, V. T., Alexander, S., Vishwanath, M., Christie, A., Xie, X. J., Williams, N. S., Kapur, P., Posner, B., McKay, R. M. & Brugarolas, J., 2015, In : Oncotarget. 6, 19, p. 16951-16962 12 p.

Research output: Contribution to journalArticle

12 Scopus citations
15 Scopus citations

Identification of CREB3L1 as a biomarker predicting doxorubicin treatment outcome

Denard, B., Pavia-Jimenez, A., Chen, W., Williams, N. S., Naina, H., Collins, R., Brugarolas, J. & Ye, J., Jun 25 2015, In : PLoS One. 10, 6, e0129233.

Research output: Contribution to journalArticle

7 Scopus citations
3 Scopus citations

Incidence and Outcomes of Delayed Targeted Therapy After Cytoreductive Nephrectomy for Metastatic Renal-Cell Carcinoma: A Nationwide Cancer Registry Study

Woldu, S. L., Matulay, J. T., Clinton, T. N., Singla, N., Freifeld, Y., Sanli, O. M., Krabbe, L. M., Hutchinson, R. C., Lotan, Y., Hammers, H., Hannan, R., Brugarolas, J. B., Bagrodia, A. & Margulis, V., Jan 1 2018, (Accepted/In press) In : Clinical Genitourinary Cancer.

Research output: Contribution to journalArticle

2 Scopus citations

Inflammatory Reaction Secondary to Immune Checkpoint Inhibitor Therapy Mimicking a Post-Operative Brain Abscess

Patel, A. R., Connors, S., Wardak, Z., Brugarolas, J. B. & Patel, T. R., Sep 1 2019, In : World Neurosurgery. 129, p. 354-358 5 p.

Research output: Contribution to journalArticle

1 Scopus citations

Inhibition of cyclin-dependent kinase 2 by p21 is necessary for retinoblastoma protein-mediated G1 arrest after γ-irradiation

Brugarolas, J., Moberg, K., Boyd, S. D., Taya, Y., Jacks, T. & Lees, J. A., Feb 2 1999, In : Proceedings of the National Academy of Sciences of the United States of America. 96, 3, p. 1002-1007 6 p.

Research output: Contribution to journalArticle

199 Scopus citations

Interplay between pVHL and mTORC1 pathways in clear-cell renal cell carcinoma

Kucejova, B., Peña-Llopis, S., Yamasaki, T., Sivanand, S., Tran, T. A. T., Alexander, S., Wolff, N. C., Lotan, Y., Xie, X-J., Kabbani, W., Kapur, P. & Brugarolas, J. B., Sep 1 2011, In : Molecular Cancer Research. 9, 9, p. 1255-1265 11 p.

Research output: Contribution to journalArticle

65 Scopus citations
14 Scopus citations

Involvement of p53 and p21 in cellular defects and tumorigenesis in Atm(-/-) mice

Xu, Y., Yang, E. M., Brugarolas, J., Jacks, T. & Baltimore, D., Jul 1998, In : Molecular and cellular biology. 18, 7, p. 4385-4390 6 p.

Research output: Contribution to journalArticle

Open Access
86 Scopus citations

Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low-risk clear cell renal cell carcinoma

Joseph, R. W., Kapur, P., Serie, D. J., Eckel-Passow, J. E., Parasramka, M., Ho, T., Cheville, J. C., Frenkel, E. P., Rakheja, D., Brugarolas, J. B. & Parker, A., Jan 1 2014, In : Cancer. 120, 7, p. 1059-1067 9 p.

Research output: Contribution to journalArticle

70 Scopus citations

Loss of DAB2IP in RCC cells enhances their growth and resistance to mTOR-targeted therapies

Zhou, J., Luo, J., Wu, K., Yun, E. J., Kapur, P., Pong, R. C., Du, Y., Wang, B., Authement, C., Hernandez, E., Yang, J., Xiao, G., Cha, T. L., Wu, H. C., Wu, D., Margulis, V., Lotan, Y., Brugarolas, J. B., He, D. & Hsieh, J-T., Feb 15 2016, (Accepted/In press) In : Oncogene.

Research output: Contribution to journalArticle

13 Scopus citations

Loss of histone H3 lysine 36 trimethylation is associated with an increased risk of renal cell carcinoma-specific death

Ho, T. H., Kapur, P., Joseph, R. W., Serie, D. J., Eckel-Passow, J. E., Tong, P., Wang, J., Castle, E. P., Stanton, M. L., Cheville, J. C., Jonasch, E., Brugarolas, J. & Parker, A. S., Oct 30 2015, (Accepted/In press) In : Modern Pathology.

Research output: Contribution to journalArticle

20 Scopus citations

Loss of PBRM1 and BAP1 expression is less common in non-clear cell renal cell carcinoma than in clear cell renal cell carcinoma

Ho, T. H., Kapur, P., Joseph, R. W., Serie, D. J., Eckel-Passow, J. E., Parasramka, M., Cheville, J. C., Wu, K. J., Frenkel, E. P., Rakheja, D., Stefanius, K., Brugarolas, J. B. & Parker, A. S., Jan 1 2015, In : Urologic Oncology: Seminars and Original Investigations. 33, 1, p. 23.e9-23.e14

Research output: Contribution to journalArticle

24 Scopus citations

Loss of Tsc1, but not Pten, in renal tubular cells causes polycystic kidney disease by activating mTORC1

Zhou, J., Brugarolas, J. & Parada, L. F., Nov 9 2009, In : Human molecular genetics. 18, 22, p. 4428-4441 14 p.

Research output: Contribution to journalArticle

36 Scopus citations

mMTORC1 activation in childhood ependymoma and response to sirolimus

Bowers, D. C., Kucejova, B., Margraf, L., Gargan, L. & Brugarolas, J., Jul 1 2011, In : Journal of Neuro-Oncology. 103, 3, p. 797-801 5 p.

Research output: Contribution to journalArticle

5 Scopus citations

Modeling renal cell carcinoma in mice: Bap1 and Pbrm1 inactivation drive tumor grade

Gu, Y. F., Cohn, S., Christie, A., McKenzie, T., Wolff, N., Do, Q. N., Madhuranthakam, A. J., Pedrosa, I., Wang, T., Dey, A., Busslinger, M., Xie, X-J., Hammer, R. E., McKay, R. M., Kapur, P. & Brugarolas, J. B., 2017, In : Cancer Discovery. 7, 8, p. 900-917 18 p.

Research output: Contribution to journalArticle

34 Scopus citations

Molecular genetics of clear-cell renal cell carcinoma

Brugarolas, J., Jun 20 2014, In : Journal of Clinical Oncology. 32, 18, p. 1968-1976 9 p.

Research output: Contribution to journalArticle

143 Scopus citations

mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways

Majumder, P. K., Febbo, P. G., Bikoff, R., Berger, R., Xue, Q., McMahon, L. M., Manolal, J., Brugarolas, J., J McDonnell, T., Golub, T. R., Loda, M., Lane, H. A. & Sellers, W. R., Jun 1 2004, In : Nature medicine. 10, 6, p. 594-601 8 p.

Research output: Contribution to journalArticle

778 Scopus citations

Multicenter validation of enhancer of zeste homolog 2 expression as an independent prognostic marker in localized clear cell renal cell carcinoma

Ho, T. H., Eckel-Passow, J. E., Cheville, J. C., Houston Thompson, R., Kapur, P., Christie, A., Panwar, V., Brugarolas, J., Homayoun, F., Joseph, R. W., Serie, D. J. & Parker, A. S., Nov 10 2017, In : Journal of Clinical Oncology. 35, 32, p. 3706-3713 8 p.

Research output: Contribution to journalArticle

12 Scopus citations
13 Scopus citations

Multistep regulation of TFEB by MTORC1

Vega-Rubin-de-Celis, S., Peña-Llopis, S., Konda, M. & Brugarolas, J., Mar 4 2017, (Accepted/In press) In : Autophagy. p. 1-9 9 p.

Research output: Contribution to journalArticle

40 Scopus citations

p21 is a critical CDK2 regulator essential for proliferation control in Rb-deficient cells

Brugarolas, J., Bronson, R. T. & Jacks, T., Apr 20 1998, In : Journal of Cell Biology. 141, 2, p. 503-514 12 p.

Research output: Contribution to journalArticle

129 Scopus citations
Open Access
7 Scopus citations

Phase I dose-escalation trial of PT2385, a first-in-class hypoxia-inducible factor-2a antagonist in patients with previously treated advanced clear cell renal cell carcinoma

Courtney, K. D., Infante, J. R., Lam, E. T., Figlin, R. A., Rini, B. I., Brugarolas, J., Zojwalla, N. J., Lowe, A. M., Wang, K., Wallace, E. M., Josey, J. A. & Choueiri, T. K., Jan 1 2018, In : Journal of Clinical Oncology. 36, 9, p. 867-874 8 p.

Research output: Contribution to journalArticle

67 Scopus citations

Platelet-derived growth factor/vascular endothelial growth factor receptor inactivation by sunitinib results in Tsc1/Tsc2-dependent inhibition of TORC1

Tran, T. A., Kinch, L., Peña-Llopis, S., Kockel, L., Grishin, N., Jiang, H. & Brugarolas, J., Nov 6 2013, In : Molecular and cellular biology. 33, 19, p. 3762-3779 18 p.

Research output: Contribution to journalArticle

10 Scopus citations